| Date | Title | Description |
| 08.11.2024 | Interim Report January-September 2024 | Interim Report January-September 2024
Fri, Nov 08, 2024 08:00 CET Report this content
Our Best Quarter in the Enzyme Business: Strong Growth and improved profitability
July – September 2024
Genovis executed a strategic acquisition of a 25% ... |
| 25.09.2024 | Genovis Unveils FabRICATOR® Xtra: A Leap Forward in Antibody Therapeutics | In the fast-paced world of biopharmaceuticals, innovation is the lifeblood. Genovis AB, a Swedish company known for its cutting-edge enzyme technologies, has just made a significant splash with the launch of FabRICATOR® Xtra. This next-gene... |
| 23.09.2024 | Genovis Launches FabRICATOR® Xtra: Next-Generation Enzyme for Future Antibody Therapeutics | Genovis Launches FabRICATOR® Xtra: Next-Generation Enzyme for Future Antibody Therapeutics
Mon, Sep 23, 2024 15:00 CET Report this content
Genovis AB, a leading provider of innovative enzyme technologies, announce the launch of FabRICATOR® ... |
| 20.08.2024 | Half-Yearly Report January - June 2024 | Half-Yearly Report January - June 2024
Tue, Aug 20, 2024 08:00 CET Report this content
A stable quarter despite subdued market conditions
April – June 2024
Net sales totaled SEK 29,470 (29,463) thousand, with a growth rate of 0.03%. Adjuste... |
| 19.08.2024 | Genovis Announces Strategic Divestment of Antibody Business to Leinco Technologies Inc. | Genovis Announces Strategic Divestment of Antibody Business to Leinco Technologies Inc.
Mon, Aug 19, 2024 19:00 CET Report this content
Genovis, a leading innovator in enzyme technology, today announced the successful divestment of its anti... |
| 04.07.2024 | Genovis completes a strategic investment in SEQURNA, a developer of next-generation RNase inhibitors | Genovis completes a strategic investment in SEQURNA, a developer of next-generation RNase inhibitors
Thu, Jul 04, 2024 14:45 CET Report this content
This strategic investment unlocks new product offerings for Genovis to both existing and ne... |
| 15.05.2024 | Communiqué from Genovis AB (publ) Annual General Meeting May 15, 2024 | Communiqué from Genovis AB (publ) Annual General Meeting May 15, 2024
Wed, May 15, 2024 18:54 CET Report this content
The Annual General Meeting adopted the following resolutions:
The Balance Sheet and Income Statement as well as the Consol... |
| 24.04.2024 | Genovis Annual Report 2023 published | Genovis Annual Report 2023 published
Wed, Apr 24, 2024 08:00 CET Report this content
Genovis 2023 Annual Report is now available in Swedish and English at our website.
To read or download the annual report in Swedish, go to:
https://investo... |
| 09.04.2024 | NOTICE CONVENING THE 2024 ANNUAL GENERAL MEETING | NOTICE CONVENING THE 2024 ANNUAL GENERAL MEETING
Tue, Apr 09, 2024 12:00 CET Report this content
Genovis AB will hold its Annual General Meeting of Shareholders at 5:00 p.m. on May 15, 2024, at Karl Johans väg 104, Kävlinge.
4:30 p.m. – 4:5... |
| 14.03.2024 | Carthesian Therapeutics terminates Genovis Licence Agreement | Carthesian Therapeutics terminates Genovis Licence Agreement
Thu, Mar 14, 2024 17:25 CET Report this content
On 21 October 2021 Genovis entered into a license agreement with Selecta Biocience/Carhtesian Therapeutics. This license agreement ... |
| 15.02.2024 | Year-end report January-December 2023 | Year-end report January-December 2023
Thu, Feb 15, 2024 08:00 CET Report this content
Our best year - focus on continued growth
October – December 2023
Net sales totaled SEK 27,306 (25,741) thousand, with a growth rate of 6%. Growth is 4%, ... |
| 13.02.2024 | Genovis to receive USD 1 million in milestone compensation related to the development of the Xork™ enzyme | Genovis to receive USD 1 million in milestone compensation related to the development of the Xork™ enzyme
Tue, Feb 13, 2024 08:20 CET Report this content
The milestone compensation is related to achieved development targets for the Xork enz... |
| 30.11.2023 | Genovis AB changes Certified Adviser to Carnegie Investment Bank AB (publ) | Genovis AB changes Certified Adviser to Carnegie Investment Bank AB (publ)
Thu, Nov 30, 2023 08:00 CET Report this content
Genovis AB today announces a change of Certified Adviser from Erik Penser Bank AB to Carnegie Investment Bank AB (pub... |
| 15.11.2023 | Interim Report January-September 2023 | Interim Report January-September 2023
Wed, Nov 15, 2023 08:00 CET Report this content
Strong growth and investments for the future
July – September 2023
Net sales totaled SEK 30,186 (22,979) thousand, with a growth rate of 31%. Growth is 25... |
| 24.08.2023 | Half-Yearly Report January-June 2023 | Half-Yearly Report January-June 2023
Thu, Aug 24, 2023 08:00 CET Report this content
Continued strong growth in both enzyme and antibody business
April – June 2023
Net sales totaled SEK 29,463 (21,093) thousand, with a growth rate of 40%. G... |
| 02.06.2023 | Genovis launch Innovative IgM-Specific Protease with Wide-Ranging Applications in Life Science Markets | Genovis launch Innovative IgM-Specific Protease with Wide-Ranging Applications in Life Science Markets
Fri, Jun 02, 2023 10:30 CET Report this content
As a leading innovator in the field of enzyme technology, Genovis today announces the lau... |
| 16.05.2023 | Communiqué from Genovis AB (publ) Annual General Meeting May 16, 2023 | Communiqué from Genovis AB (publ) Annual General Meeting May 16, 2023
Tue, May 16, 2023 18:33 CET Report this content
The Board withdrew its proposal regarding authorizing the Board of Directors to decide on the issuance of shares, item 17 ... |
| 16.05.2023 | Interim Report January-March 2023 | Interim Report January-March 2023
Tue, May 16, 2023 08:00 CET Report this content
Record earnings and strong growth in all areas of the business
January-March 2023
Net sales totaled SEK 71,276 (32,574) thousand, with a growth rate of 119%. ... |
| 03.05.2023 | Genovis and ArcticZymes Technologies enter into a collaboration agreement to accelerate growth in China | Genovis and ArcticZymes Technologies enter into a collaboration agreement to accelerate growth in China
Wed, May 03, 2023 13:00 CET Report this content
Genovis and ArcticZymes are excited to announce a collaboration to speed up penetration ... |
| 25.04.2023 | Genovis Annual Report 2022 published | Genovis Annual Report 2022 published
Tue, Apr 25, 2023 11:15 CET Report this content
Genovis 2022 Annual Report is now available in Swedish and English at our website.
To read or download the annual report in Swedish, go to:
Årsredovisning ... |
| 25.04.2023 | Genovis acquires IP Rights to novel enzymes for applications within genomics | Genovis acquires IP Rights to novel enzymes for applications within genomics
Tue, Apr 25, 2023 15:00 CET Report this content
Today, Genovis has acquired the patent rights to a unique DNA polymerase developed by researchers at Uppsala Univer... |
| 11.04.2023 | NOTICE CONVENING THE 2023 ANNUAL GENERAL MEETING | NOTICE CONVENING THE 2023 ANNUAL GENERAL MEETING
Tue, Apr 11, 2023 12:30 CET Report this content
Genovis AB will hold its Annual General Meeting of Shareholders at 5:00 p.m. on Tuesday, May 16, 2023 at Medicon Village Scheeletorget 1, Lund ... |
| 15.02.2023 | Year-end Report January-December 2022 | Year-end Report January-December 2022
Wed, Feb 15, 2023 08:00 CET Report this content
The strong growth in the core business during the fourth quarter continues in the beginning of 2023
October-December 2022
Net sales totaled SEK 25,741 (42... |
| 09.01.2023 | Genovis to receive 4 MUSD upfront after Selecta Biosciences sublicensed Xork™ enzyme to Astellas Pharma | Genovis to receive 4 MUSD upfront after Selecta Biosciences sublicensed Xork™ enzyme to Astellas Pharma
Mon, Jan 09, 2023 13:57 CET Report this content
Today Selecta Biosciences announced the sublicensing of the Xork enzyme to Astellas Phar... |
| 12.08.2022 | Half-Year Report for the First Half of 2022 | Half-Year Report for the First Half of 2022
Fri, Aug 12, 2022 08:00 CET Report this content
April – June 2022
Net sales totaled SEK 21,093 (19,535) thousand, with a growth rate of 8%. Growth is -4%, adjusted for currency effects.
Gross prof... |
| 10.08.2022 | Genovis enters licensing and supply agreement with new bioprocess customer | Genovis enters licensing and supply agreement with new bioprocess customer
Wed, Aug 10, 2022 14:00 CET Report this content
Genovis has signed a long-term licensing and supply agreement with a US based biotech company for the supply of Smart... |
| 04.08.2022 | Genovis AB enters service agreement with evitria AG for fast LC-MS analysis of recombinant antibodies | Genovis AB enters service agreement with evitria AG for fast LC-MS analysis of recombinant antibodies
Thu, Aug 04, 2022 13:00 CET Report this content
Genovis AB and evitria AG today signed a service agreement to offer evitria’s customers fa... |
| 12.05.2022 | Communiqué from Genovis AB (publ) Annual General Meeting May 12, 2022 | Communiqué from Genovis AB (publ) Annual General Meeting May 12, 2022
Thu, May 12, 2022 11:56 CET Report this content
The Annual General Meeting adopted the following resolutions:
The Balance Sheet and Income Statement as well as the Consol... |
| 27.04.2022 | Interim Report January – March 2022 | Interim Report January – March 2022
Wed, Apr 27, 2022 08:00 CET Report this content
Net sales totaled SEK 32,574 (15,723) thousand, with a growth rate of 107%. About SEK 10 million relates to the license agreement in 2021 with Selecta Biosc... |
| 21.04.2022 | Genovis Annual Report 2021 published | Genovis Annual Report 2021 published
Thu, Apr 21, 2022 08:00 CET Report this content
Genovis 2021 Annual Report is now available in Swedish and English at our website.
To read or download the annual report in Swedish, go to:
https://investo... |
| 06.04.2022 | NOTICE CONVENING THE 2022 ANNUAL GENERAL MEETING | NOTICE CONVENING THE 2022 ANNUAL GENERAL MEETING
Wed, Apr 06, 2022 14:33 CET Report this content
The shareholders of Genovis AB, corporate identity no 556574-5345, are hereby given notice of the Annual General Meeting on Thursday, May 12, 2... |
| 08.02.2022 | Year-end Report January - December 2021 | Year-end Report January - December 2021
Tue, Feb 08, 2022 08:00 CET Report this content
October – December 2021
Net sales rose by 112% to SEK 42,060 (19,850) thousand. About SEK 20 million relates to licensing agreements with Selecta Biosci... |
| 12.11.2021 | INTERIM REPORT FOR July – September 2021 | INTERIM REPORT FOR July – September 2021 Fri, Nov 12, 2021 12:00 CET
July – September 2021
Net sales rose by 10% to SEK 15,699 (14,216) thousand. Growth is 13%, adjusted for currency effects.
Gross profit declined by 8% to SEK 14,195 (15,48... |
| 06.10.2021 | Genovis AB (publ.) hires new CFO | Genovis AB (publ.) hires new CFO Wed, Oct 06, 2021 08:35 CET
Genovis has hired Magnus Långberg as the new CFO of the Group; he will begin in January 2022.
Magnus Långberg has over 20 years of experience from a variety of positions within fi... |
| 12.08.2021 | HALF-YEAR REPORT FOR THE FIRST HALF OF 2021 | HALF-YEAR REPORT FOR THE FIRST HALF OF 2021 Thu, Aug 12, 2021 08:05 CET
Second quarter 2021
Net sales rose by 26% to SEK 19,535 (15,490) thousand. Growth is 37%, adjusted for currency effects.
Gross profit rose by 32% to SEK 17,365 (13,146)... |
| 07.06.2021 | Genovis and GlycoT Therapeutics enter into cross-licensing agreements on novel antibody conjugation technology | Genovis and GlycoT Therapeutics enter into cross-licensing agreements on novel antibody conjugation technology Mon, Jun 07, 2021 15:02 CET
Under the agreements, the combined proprietary technology platform will enable Genovis and GlycoT The... |
| 20.05.2021 | Communiqué from Genovis AB (publ) Annual General Meeting May 20, 2021 | Communiqué from Genovis AB (publ) Annual General Meeting May 20, 2021 Thu, May 20, 2021 11:09 CET
The Annual General Meeting adopted the following resolutions:
The Balance Sheet and Income Statement as well as the Consolidated Income Statem... |
| 13.04.2021 | GENOVIS AB (PUBL.)
Genovis : and Waters Collaborate to Develop Efficient Workflows for Biopharmaceutical Characterization | Firms Working to Co-Develop Automated Biotherapeutic Characterization Workflows, Combining Genovis SmartEnzymes™ and Waters LC-MS Instrumentation.
Collaboration intended to bring speed and simplicity to bio-characterization workflows
Automa... |
